non-small cell lung cancer

Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials
Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials
CP Wire
Mirati Therapeutics
Opdivo
checkpoint inhibitors
non-small cell lung cancer
Flag link:
Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials
Mirati Therapeutics
Opdivo
checkpoint inhibitors
non-small cell lung cancer
Flag link:
Roche Receives FDA Approval for New Indication for cobas EGFR Mutation Test v2 as a Companion Diagnostic With Tagrisso
Roche Receives FDA Approval for New Indication for cobas EGFR Mutation Test v2 as a Companion Diagnostic With Tagrisso
CP Wire
Roche
cobas EGFR Mutation Test
Tagrisso
non-small cell lung cancer
AstraZeneca
Flag link:
Roche Receives FDA Approval for New Indication for cobas EGFR Mutation Test v2 as a Companion Diagnostic With Tagrisso
Roche
Tagrisso
non-small cell lung cancer
Flag link:
Merck, Bristol-Myers cancer drugs both beat expectations, but Merck beats them a little more
Merck, Bristol-Myers cancer drugs both beat expectations, but Merck beats them a little more
CNBC
Merck
Bristol-Myers Squibb
Keytruda
Opdivo
Yervoy
non-small cell lung cancer
AACR
Flag link:
We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated
We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated
San Francisco Gate, CA
lung cancer
cancer
Merck
Roche
Bristol-Myers Squibb
AACR
non-small cell lung cancer
Flag link:
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
Yahoo/Zacks.com
AstraZeneca
FDA
Imfinzi
non-small cell lung cancer
Flag link:
AstraZeneca's Tagrisso Label Expansion Filing Accepted by FDA
AstraZeneca's Tagrisso Label Expansion Filing Accepted by FDA
Yahoo/Zacks.com
AstraZeneca
Tagrisso
FDA
labeling
non-small cell lung cancer
Flag link:
Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC
Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC
BioPharma Dive
clinical trials
AstraZeneca
Mystic
Imfinzi
non-small cell lung cancer
Flag link:
Recent Developments for Merck’s Keytruda
Recent Developments for Merck’s Keytruda
Market Realist
Merck
Keytruda
immuno-oncology
anti-PD-1 immunotherapy
non-small cell lung cancer
Flag link:
AstraZeneca touts Tagrisso's CNS benefit
AstraZeneca touts Tagrisso's CNS benefit
BioPharma Dive
Tagrisso
AstraZeneca
non-small cell lung cancer
CNS metastases
Flag link:
Here's Why Merck & Co., Inc. Tanked 14% in October
Here's Why Merck & Co., Inc. Tanked 14% in October
Motley Fool
Merck
Keytruda
Europe
non-small cell lung cancer
Flag link:
FDA adds fresh ‘breakthrough’ for Novartis’ cancer combo Tafinlar and Mekinist
FDA adds fresh ‘breakthrough’ for Novartis’ cancer combo Tafinlar and Mekinist
Endpoints
FDA
Novartis
Tafinlar
Mekinist
non-small cell lung cancer
Flag link:
Hunting an early FDA OK, Ignyta surges on promising snapshot of lung cancer data
Hunting an early FDA OK, Ignyta surges on promising snapshot of lung cancer data
Endpoints
Ignyta
entrectinib
non-small cell lung cancer
Flag link:
After getting skunked by rivals, Pfizer touts ‘breakthrough’ cancer drug lorlatinib, heads to the FDA
After getting skunked by rivals, Pfizer touts ‘breakthrough’ cancer drug lorlatinib, heads to the FDA
Endpoints
Pfizer
lorlatinib
FDA
non-small cell lung cancer
Flag link:
Lilly's lung cancer drug fails main goal of key study
Lilly's lung cancer drug fails main goal of key study
Yahoo/Reuters
Eli Lilly
lung cancer
clinical trials
Verzenio
non-small cell lung cancer
Flag link:
AbbVie pairs up another ADC cancer drug with Bristol-Myers Squibb's Opdivo
AbbVie pairs up another ADC cancer drug with Bristol-Myers Squibb's Opdivo
Fierce Biotech
AbbVie
Bristol-Myers Squibb
Opdivo
ABBV-399
antibody-drug conjugate
non-small cell lung cancer
Flag link:
Merck's new Keytruda flat dose could add $1B each year to U.S. healthcare spending
Merck's new Keytruda flat dose could add $1B each year to U.S. healthcare spending
Fierce Pharma
Merck
Keytruda
drug pricing
non-small cell lung cancer
Flag link:
FDA approves diagnostic that simultaneously screens for multiple cancer biomarkers
FDA approves diagnostic that simultaneously screens for multiple cancer biomarkers
Drug Delivery Business News
FDA
Thermofisher
diagnostics
biomarkers
non-small cell lung cancer
Oncomine Dx Target Test
Flag link:
Novartis picks up FDA approval for targeted lung cancer meds Tafinlar, Mekinist
Novartis picks up FDA approval for targeted lung cancer meds Tafinlar, Mekinist
Fierce Pharma
Novartis
FDA
Tafinlar
Mekinist
non-small cell lung cancer
BRAF V600
Flag link:

Pages